Personalized medicine in adult acute lymphoblastic leukemia.
作者信息
Hoelzer Dieter
机构信息
Onkologikum Frankfurt am Museumsufer, Frankfurt, Germany
出版信息
Haematologica. 2015 Jul;100(7):855-8. doi: 10.3324/haematol.2015.127837.
Abstract
摘要
相似文献
1
Personalized medicine in adult acute lymphoblastic leukemia.
Haematologica. 2015 Jul;100(7):855-8. doi: 10.3324/haematol.2015.127837.
2
Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia.
Leukemia. 2005 Apr;19(4):628-35. doi: 10.1038/sj.leu.2403683.
3
Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients.
Leukemia. 2016 Jul;30(7):1615-9. doi: 10.1038/leu.2016.17. Epub 2016 Feb 12.
4
Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease.
J Clin Oncol. 2014 Sep 20;32(27):3012-20. doi: 10.1200/JCO.2014.55.4105.
5
Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatment.
Leukemia. 2003 Sep;17(9):1700-6. doi: 10.1038/sj.leu.2403062.
6
[Molecular genetic detection of minimal residual disease (MRD) in children with acute lymphoblastic leukemia].
Klin Padiatr. 2013 May;225 Suppl 1:S40-4. doi: 10.1055/s-0033-1337962. Epub 2013 May 22.
7
Post-induction residual disease in translocation t(12;21)-positive childhood ALL.
Med Pediatr Oncol. 2003 Feb;40(2):82-7. doi: 10.1002/mpo.10217.
8
Prevalence of common fusion transcripts in acute lymphoblastic leukemia: A report of 304 cases.
Asia Pac J Clin Oncol. 2015 Dec;11(4):293-8. doi: 10.1111/ajco.12400. Epub 2015 Aug 12.
9
Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia.
Haematologica. 2015 Mar;100(3):295-9. doi: 10.3324/haematol.2015.124016.
10
Management of adult patients with Philadelphia positive acute lymphoblastic leukemia.
Rinsho Ketsueki. 2013 Oct;54(10):1828-37.
引用本文的文献
1
Highly sensitive single tube B-lymphoblastic leukemia/lymphoma minimal/measurable residual disease test robust to surface antigen directed therapy.
Cytometry B Clin Cytom. 2023 Jul;104(4):279-293. doi: 10.1002/cyto.b.22120. Epub 2023 Mar 30.
2
Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical Advances.
Front Oncol. 2019 Aug 7;9:726. doi: 10.3389/fonc.2019.00726. eCollection 2019.
3
A systematic literature review and meta-analysis of minimal residual disease as a prognostic indicator in adult B-cell acute lymphoblastic leukemia.
Haematologica. 2019 Oct;104(10):2028-2039. doi: 10.3324/haematol.2018.201053. Epub 2019 Mar 19.
4
Clinician Concepts of Cure in Adult Relapsed and Refractory Philadelphia-Negative B Cell Precursor Acute Lymphoblastic Leukemia: A Delphi Study.
Adv Ther. 2019 Apr;36(4):870-879. doi: 10.1007/s12325-019-00910-z. Epub 2019 Mar 7.
5
Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia.
J Hematol Oncol. 2018 Aug 1;11(1):99. doi: 10.1186/s13045-018-0641-1.
6
Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretation.
Blood Adv. 2017 Nov 28;1(25):2456-2466. doi: 10.1182/bloodadvances.2017009845.
7
Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretation.
Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):13-21. doi: 10.1182/asheducation-2017.1.13.
8
The impact of RNA sequence library construction protocols on transcriptomic profiling of leukemia.
BMC Genomics. 2017 Aug 17;18(1):629. doi: 10.1186/s12864-017-4039-1.
9
Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia.
Drug Des Devel Ther. 2016 Feb 18;10:757-65. doi: 10.2147/DDDT.S83848. eCollection 2016.
本文引用的文献
1
Change in prognostic factors.
Leuk Suppl. 2012 Aug;1(Suppl 2):S1-2. doi: 10.1038/leusup.2012.4. Epub 2012 Aug 9.
2
T-cell and natural killer cell therapies for hematologic malignancies after hematopoietic stem cell transplantation: enhancing the graft-versus-leukemia effect.
Haematologica. 2015 Jun;100(6):709-19. doi: 10.3324/haematol.2014.113860.
3
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.
Lancet Oncol. 2015 Jan;16(1):57-66. doi: 10.1016/S1470-2045(14)71170-2. Epub 2014 Dec 16.
4
Ph-like acute lymphoblastic leukemia in older adults.
N Engl J Med. 2014 Dec 4;371(23):2235. doi: 10.1056/NEJMc1412123#SA1.
5
Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial.
Blood. 2014 Dec 18;124(26):3870-9. doi: 10.1182/blood-2014-03-563627. Epub 2014 Oct 30.
6
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.
N Engl J Med. 2014 Sep 11;371(11):1005-15. doi: 10.1056/NEJMoa1403088.
7
Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial.
J Clin Oncol. 2014 May 20;32(15):1595-604. doi: 10.1200/JCO.2013.52.2425. Epub 2014 Apr 21.
8
Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia.
Blood. 2014 Jun 12;123(24):3739-49. doi: 10.1182/blood-2014-01-547695. Epub 2014 Apr 16.
9
A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.
N Engl J Med. 2013 Nov 7;369(19):1783-96. doi: 10.1056/NEJMoa1306494. Epub 2013 Nov 1.
10
How I treat older patients with ALL.
Blood. 2013 Aug 22;122(8):1366-75. doi: 10.1182/blood-2012-07-379016. Epub 2013 May 14.
Zotero 插件